AUTHOR=Chen Xindong , Zhou Zhiruo , Zhang Zhi , Zhao Chenhao , Li Jiayu , Jiang Jingwen , Huang Biao , Qin Yuan 

TITLE=Puerarin inhibits EMT induced by oxaliplatin via targeting carbonic anhydrase XII

JOURNAL=Frontiers in Pharmacology

VOLUME=13

YEAR=2022

URL=https://www.frontiersin.org/journals/pharmacology/articles/10.3389/fphar.2022.969422

DOI=10.3389/fphar.2022.969422

ISSN=1663-9812

ABSTRACT=<p>Puerarin is a flavonoid molecule that widely exists in various plants. Puerarin has been reported to exhibit anti-tumor effects in various cancers. However, its exact underlying pharmacological mechanism is unclear. This study evaluated the anticancer effect of puerarin combined with oxaliplatin (OXA) <italic>in vitro</italic> and <italic>in vivo</italic>. Our results indicated that puerarin can reverse platinum-based anti-cancer drug resistance, and enhance the OXA’s anticancer effects on breast cancer. Furthermore, puerarin can inhibit migration and reverse the epithelial-mesenchymal transition (EMT) induced by low-dose OXA. Further studies showed that the carbonic anhydrase (CA) XII is a potential target of puerarin. In conclusion, puerarin is expected to become an adjuvant chemotherapy drug and potentially become one of the medicated foods for breast cancer patients.</p>